On January 11, 2022, the U.S. Centers for Medicare and Medicaid Services (CMS) announced that Biogen's monoclonal antibody drug Aducanumab (trade name: Aduhelm) will be included in the Medicare list, but only for patients participating in clinical trials. The drug sells for $56,000 per year.
At present, this medical insurance list has not yet been implemented, and CMS will publicly seek the opinions of Alzheimer's patients, their families and professionals within 30 days.
Image source: CMS official website
Lee Fleisher, chief medical officer at CMS, said that while the drug has the potential to treat Alzheimer's, it also has the potential to cause harm to patients, such as headaches, dizziness, cerebral hemorrhages and more. Therefore, he believes that it is more correct to limit the scope of reimbursement of this drug to patients participating in clinical trials.
Planner: Cat, z_popeye
Executive Producer: Gyouza
Source: Centers for Medicare & Medicaid Services website
![Experience golf in the Jia Travel with 1.4T power, large space can be installed, fragrant or not?[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)